Karyopharm Therapeutics Inc. Debt Securities, Available-for-sale, Current
Karyopharm Therapeutics Inc. (KPTI) had Debt Securities, Available-for-sale, Current of $10.13 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent · last filed 2026-08-13
- 2026-06-30: Debt Securities, Available-for-sale, Current $10.13M.
- 2026-03-31: Debt Securities, Available-for-sale, Current $0.00.
- 2025-12-31: Debt Securities, Available-for-sale, Current $3.20M.
- 2025-09-30: Debt Securities, Available-for-sale, Current $8.21M.
| Period end | Debt Securities, Available-for-sale, Current |
|---|---|
| 2026-06-30 | $10.13M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-14 |
| 2025-12-31 | $3.20M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $8.21M 10-Q · filed 2025-11-03 |
| 2025-06-30 | $12.97M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $31.16M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $46.24M 10-K · filed 2026-02-13 |
| 2024-09-30 | $60.70M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $67.35M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $117.95M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $139.21M 10-K · filed 2025-02-19 |
| 2023-09-30 | $164.66M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $155.87M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $176.32M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $142.78M 10-K · filed 2024-02-29 |
| 2022-09-30 | $77.03M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $88.60M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $52.05M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $38.16M 10-K · filed 2023-02-17 |
| 2021-09-30 | $66.81M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $94.58M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $135.89M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $163.32M 10-K · filed 2022-03-01 |
| 2020-09-30 | $180.74M 10-Q · filed 2020-11-02 |
| 2020-06-30 | $193.62M 10-Q · filed 2020-08-04 |
| 2020-03-31 | $149.88M 10-Q · filed 2020-05-05 |
| 2019-12-31 | $133.10M 10-K · filed 2021-02-24 |
| 2019-09-30 | $99.53M 10-Q · filed 2019-11-04 |
| 2019-06-30 | $141.61M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $180.92M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $210.18M 10-K · filed 2020-02-26 |
| 2018-09-30 | $105.17M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $122.16M 10-Q · filed 2018-08-07 |
| 2017-12-31 | $77.47M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |